Jaskiran Kaur

Jaskiran Kaur

Auto-generated profile, based on publicly available information

Jaskiran Kaur

Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
RKRajan Kumar
Rajan Kumar
RKRakesh Kumar
Rakesh Kumar
NKNavneet Khurana
Navneet Khurana
SSSachin Kumar Singh
Sachin Kumar Singh
SKShelly Khurana
Shelly Khurana
LCLeander Corrie
Leander Corrie

28 January 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LCLeander Corrie
Leander Corrie
AAAnkit Awasthi
Ankit Awasthi
JKJaskiran Kaur
Jaskiran Kaur
SVSukriti Vishwas
Sukriti Vishwas
DGDr. Monica Gulati
Dr. Monica Gulati
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
Polycystic Ovarian Syndrome (PCOS) comprises a set of symptoms that pose significant risk factors for various diseases, including type 2 diabetes, cardiovascular disease, and cancer. Effective and safe methods to treat all the pathological symptoms of PCOS are not available. The gut microbiota has been shown to play an essential role in PCOS incidence and progression. Many dietary plants, prebiotics, and probiotics have been reported to ameliorate PCOS. Gut microbiota shows its effects in PCOS via a number of mechanistic pathways including maintenance of homeostasis, regulation of lipid and blood glucose levels. The effect of gut microbiota on PCOS has been widely reported in animal models but there are only a few reports of human studies. Increasing the diversity of gut microbiota, and up-regulating PCOS ameliorating gut microbiota are some of the ways through which prebiotics, probiotics, and polyphenols work. We present a comprehensive review on polyphenols from natural origin, probiotics, and fecal microbiota therapy that may be used to treat PCOS by modifying the gut microbiota.

1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AAAnkit Awasthi
Ankit Awasthi
DGDr. Monica Gulati
Dr. Monica Gulati
BKBIMLESH KUMAR
BIMLESH KUMAR
JKJaskiran Kaur
Jaskiran Kaur
SVSukriti Vishwas
Sukriti Vishwas
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
Diabetic wound (DW) is a secondary application of uncontrolled diabetes and affects about 42.2% of diabetics. If the disease is left untreated/uncontrolled, then it may further lead to amputation of organs. In recent years, huge research has been done in the area of wound dressing to have a better maintenance of DW. These include gauze, films, foams or, hydrocolloid‐based dressings as well as polysaccharide‐ and polymer‐based dressings. In recent years, scaffolds have played major role as biomaterial for wound dressing due to its tissue regeneration properties as well as fluid absorption capacity. These are three‐dimensional polymeric structures formed from polymers that help in tissue rejuvenation. These offer a large surface area to volume ratio to allow cell adhesion and exudate absorbing capacity and antibacterial properties. They also offer a better retention as well as sustained release of drugs that are directly impregnated to the scaffolds or the ones that are loaded in nanocarriers that are impregnated onto scaffolds. The present review comprehensively describes the pathogenesis of DW, various dressings that are used so far for DW, the limitation of currently used wound dressings, role of scaffolds in topical delivery of drugs, materials used for scaffold fabrication, and application of various polymer‐based scaffolds for treating DW.

6 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LCLeander Corrie
Leander Corrie
JKJaskiran Kaur
Jaskiran Kaur
AAAnkit Awasthi
Ankit Awasthi
SVSukriti Vishwas
Sukriti Vishwas
DGDr. Monica Gulati
Dr. Monica Gulati
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
The study was initiated with two major purposes: investigating the role of isomalt (GIQ9) as a pharmaceutical carrier for solid self-nanoemulsifying drug delivery systems (S-SNEDDSs) and improving the oral bioavailability of lipophilic curcumin (CUN). GIQ9 has never been explored for solidification of liquid lipid-based nanoparticles such as a liquid isotropic mixture of a SNEDDS containing oil, surfactant and co-surfactant. The suitability of GIQ9 as a carrier was assessed by calculating the loading factor, flow and micromeritic properties. The S-SNEDDSs were prepared by surface adsorption technique. The formulation variables were optimized using central composite design (CCD). The optimized S-SNEDDS was evaluated for differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), microscopy, dissolution and pharmacokinetic studies. The S-SNEDDS showed a particle size, zeta potential and PDI of 97 nm, −26.8 mV and 0.354, respectively. The results of DSC, XRD, FTIR and microscopic studies revealed that the isotropic mixture was adsorbed onto the solid carrier. The L-SNEDDS and S-SNEDDS showed no significant difference in drug release, indicating no change upon solidification. The optimized S-SNEDDS showed 5.1-fold and 61.7-fold enhancement in dissolution rate and oral bioavailability as compared to the naïve curcumin. The overall outcomes of the study indicated the suitability of GIQ9 as a solid carrier for SNEDDSs.

1 May 2021 in Current Diabetes Reviews
Verified
Journal Article
Closed access
PDF file
AAAnkit Awasthi
Ankit Awasthi
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
BKBIMLESH KUMAR
BIMLESH KUMAR
DGDr. Monica Gulati
Dr. Monica Gulati
RKRajesh Kumar
Rajesh Kumar
AYAnkit Yadav
Ankit Yadav
Background: Diabetic foot ulcer (DFU) is one of the leading complications of type-2 diabetes mellitus. It is associated with neuropathy and peripheral arterial disease of the lower limb in patients with diabetes. There are four stages of wound healing, namely hemostasis phase, inflammatory phase, proliferative phase and maturation phase. In the case of DFU, all these stages are disturbed which lead to delay in healing and consequently to lower limb amputation. Conventional dosage forms like tablets, creams, ointments, gels and capsules have been used for the treatment of diabetic foot ulcer for many years. Introduction: In this review, the global prevalence as well as etiopathogenesis related to diabetic foot ulcer have been discussed. The potential role of various synthetic and herbal drugs, as well as their conventional dosage forms in the effective management of DFU have been discussed in detail. Methods: Structured search of bibliographic databases from previously published peer-reviewed research papers was explored and data has been represented in terms of various approaches that are used for the treatment of DFU. Results: About 148 papers, including both research and review articles, were included in this review to produce a comprehensive as well as a readily understandable article. A series of herbal and synthetic drugs have been discussed along with their current status of treatment in terms of dose and mechanism of action. Conclusion: DFU has become one of the most common complications in patients having diabetes for more than ten years. Hence, understanding the root cause and its successful treatment is a big challenge because it depends upon multiple factors such as the judicious selection of drugs as well as proper control of blood sugar level. Most of the drugs that have been used so far either belong to the category of antibiotics, antihyperglycaemic or they have been repositioned. In clinical practice, much focus has been given to dressings that have been used to cover the ulcer. The complete treatment of DFU is still a farfetched dream to be achieved and it is expected that combination therapy of herbal and synthetic drugs with multiple treatment pathways could be able to offer better management of DFU.

20 June 2022 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
JKJaskiran Kaur
Jaskiran Kaur
DGDr. Monica Gulati
Dr. Monica Gulati
FZFlavia Zacconi
Flavia Zacconi
HDHarish Dureja
Harish Dureja
Raimar LöbenbergRaimar Löbenberg
Raimar Löbenberg
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
Diabetes mellitus (DM) is the most common metabolic disease and multifactorial, harming patients worldwide. Extensive research has been carried out in the search for novel drug delivery systems off...